YOU Determine the Success We need you to thrive
10.1016/j.mcn.2013.03.003 24 JiangH.ShaS.-H
Long-Term Safety Monitoring Results Clinical trials lasting 6 to 12 months may never detect ADA formation, which develops over extended use
Molewaterplein 40, 3015 GD Rotterdam, The Netherlands Tel: +31-107032861, Fax: +31-107033639, E-mail: a.vanderlelij@erasmusmcnl Received: October 30, 2023 Revised: November 23, 2023 Accepted: December 6, 2023 Copyright 2024 Korean Endocrine Society This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License ( which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited
Screened during initial evaluation
Sequestosome 1/p62 is a polyubiquitin chain binding protein involved in ubiquitin proteasome degradation